Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Edgewise Therapeutics, Inc. EWTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$38.67
+16.6%

Edgewise Therapeutics, Inc. (EWTX) is a Biotechnology company in the Healthcare sector, currently trading at $33.16. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is EWTX = $39 (+16.6% upside).

Valuation: EWTX trades at a trailing Price-to-Earnings (P/E) of -20.3 (S&P 500 average ~25).

Net income is $168M (loss), growing at -203.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $4M against $522M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 19.85 (strong liquidity). Debt-to-assets is 0.7%. Total assets: $553M.

Analyst outlook: 7 / 9 analysts rate EWTX as buy (78%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 46/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 79/100 (Pass), Income ?/100 (Fail).

$38.67
▲ 16.62% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Edgewise Therapeutics, Inc., the average price target is $38.67, with a high forecast of $46.00, and a low forecast of $25.00.
Highest Price Target
$46.00
Average Price Target
$38.67
Lowest Price Target
$25.00

EWTX SharesGrow Score Overview

56/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 46/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 79/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — EWTX

~
VALUE Partial
46/100
EWTX trades at a trailing Price-to-Earnings (P/E) of -20.3 (S&P 500 average ~25). Forward PEG -2.03 — Peter Lynch undervalued (≤1.0). Trailing PEG 6.41. Analyst consensus target is $39, implying +17.6% from the current price $33. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
EWTX: +0%/yr revenue is, -203.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet EWTX: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 19.85 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
EWTX: Gross margin is 0% (+0 pp trend), $4B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
79/100
Analyst outlook: 7 / 9 analysts rate EWTX as buy (78%). Analyst consensus target is $39 (+17.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range10.6-33.555
Volume1.05M
Avg Volume (30D)931.93K
Market Cap$3.56B
Beta (1Y)0.25
Share Statistics
EPS (TTM)-1.63
Shares Outstanding$102.93M
IPO Date2021-03-26
Employees117
CEOKevin Koch
Financial Highlights & Ratios
Gross Profit$-2.27M
EBITDA$-165.53M
Net Income$-167.8M
Operating Income$-191.41M
Total Cash$530.11M
Total Debt$3.99M
Net Debt$-57.16M
Total Assets$552.6M
Price / Earnings (P/E)-20.3
Analyst Forecast
1Y Price Target$45.00
Target High$46.00
Target Low$25.00
Upside+35.7%
Rating ConsensusBuy
Analysts Covering9
Buy 78% Hold 11% Sell 11%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS28036F1057

Price Chart

Track all markets on TradingView
EWTX
Edgewise Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
10.60 52WK RANGE 33.56

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 CELC
CELC
Celcuity Inc.
$120.85
+0.37%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.76
+0.91%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message